Trials / Terminated
TerminatedNCT00085761
Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
An International, Multicenter, Randomized, Double-Blind, 12-Week Controlled Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- NeurogesX · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful HIV-associated neuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capsaicin Dermal Patch |
Timeline
- First posted
- 2004-06-17
- Last updated
- 2008-03-06
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00085761. Inclusion in this directory is not an endorsement.